Research methodology: Cancer cachexia syndrome

Palliative Medicine

Volumn 18, Issue 5, 2004, Pages 409-417

  Dahele, Max ^a   Fearon, K C H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cancer cachexia; Physical activity; Trials and end points

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL RESPONSE MODIFIER; MEGESTROL ACETATE; PLACEBO; PREDNISOLONE; PROTEASOME; UBIQUITIN;

AMBULATORY MONITORING; BODY COMPOSITION; CACHEXIA; CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENERGY EXPENDITURE; FUNCTIONAL ASSESSMENT; HUMAN; LEAN BODY WEIGHT; METHODOLOGY; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PROGNOSIS; QUALITY OF LIFE; REVIEW; SURVIVAL; WEIGHT GAIN; WEIGHT REDUCTION;

AMBULATORY CARE; BIOMEDICAL RESEARCH; BODY COMPOSITION; CACHEXIA; EXERCISE; HUMANS; NEOPLASMS; NUTRITIONAL STATUS; PLACEBO EFFECT; PROGNOSIS; QUALITY OF LIFE; WEIGHT GAIN;

EID: 4444308166     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1191/0269216304pm906ra     Document Type: Review

References (58)

1. Raiten DJ. Clinical trials for the treatment of secondary wasting and cachexia: selection of appropriate endpoints, May 22-23, 1997, Bethesda, MD. Nutrition 1999; 129: 2235-45.
2. MacDonald N, Easson AM, Mazurak VC, Dunn GP, Baracos VE. Understanding and managing cancer cachexia. J Am Coll Surg 2003; 197: 143-61.
3. Jatoi A, Daly BD, Hughes VA, Dallal GE, Kehayias J, Roubenoff R. Do patients with nonmetastatic non-small cell lung cancer demonstrate altered resting energy expenditure? Ann Thorac Surg 2001; 72: 348-51.
4. Hyltander A, Drott C, Korner U, Sandstrom R, Lundholm K. Elevated energy expenditure in cancer patients with solid tumours. Eur J Cancer 1991; 27: 9-15.
5. Nixon DW, Kutner M, Heymsfield S, et al. Resting energy expenditure in lung and colon cancer. Metabolism 1988; 37: 1059-64.
6. Knox LS, Crosby LO, Feurer ID, Buzby GP, Miller CL, Mullen JL. Energy expenditure in malnourished cancer patients. Ann Surg 1983; 197: 152-62.
7. Fredrix EW, Soeters PB, Wouters EF, Deerenberg IM, von Meyenfeldt MF, Saris WH. Effect of different tumor types on resting energy expenditure. Cancer Res 1991; 51: 6138-41.
8. Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994; 219: 325-31.
9. Fredrix EW, Soeters PB, Rouflart MJ, von Meyenfeldt MF, Saris WH. Resting energy expenditure in patients with newly detected gastric and colorectal cancers. Am J Clin Nutr 1991; 53: 1318-22.
10. Tisdale MJ. Loss of skeletal muscle in cancer: biochemical mechanisms. Front Biosci 2001; 6: D164-74.
11. Fearon KC, Hansell DT, Preston T, et al. Influence of whole body protein turnover rate on resting energy expenditure in patients with cancer. Cancer Res 1988; 48: 2590-95.
12. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M. Characterization of a cancer cachectic factor. Nature 1996; 379: 739-42.
13. Zuijdgeest-van Leeuwen SD, van den Berg JW, Wattimena JL, et al. Lipolysis and lipid oxidation in weight-losing cancer patients and healthy subjects. Metabolism 2000; 49: 931-36.
14. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69: 491-97.
15. Wigmore SJ, Plester CE, Richardson RA, Fearon KC. Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 1997; 75: 106-109.
16. Scott HR, McMillan DC, Brown DJ, Forrest LM, McArdle CS, Milroy R. A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer. Lung Cancer 2003; 40: 295-99.
17. Persson C, Glimelius B. The relevance of weight loss for survival and quality of life in patients with advanced gastrointestinal cancer treated with palliative chemotherapy. Anticancer Res 2002; 22: 3661-68.
18. Buccheri G, Ferrigno D. Importance of weight loss definition in the prognostic evaluation of non-small-cell lung cancer. Lung Cancer 2001; 34: 433-40.
19. O'Gorman P, McMillan DC, McArdle CS. Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutr Cancer 1998; 32: 76-80.
20. O'Gorman P, McMillan DC, McArdle CS. Longitudinal study of weight, appetite, performance status, and inflammation in advanced gastrointestinal cancer. Nutr Cancer 1999; 35: 127-29.
21. O'Gorman P, McMillan DC, McArdle CS. Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer 2000; 37: 36-40.
22. McMillan DC, Scott HR, Watson WS, Preston T, Milroy R, McArdle CS. Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr Cancer 1998; 31: 101-105.
23. Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998; 34: 503-9.
24. Yan LL, Daviglus ML, Liu K, et al. BMI and health-related quality of life in adults 65 years and older. Obes Res 2004; 12: 69-76.
25. Chvetzoff G, Tannock IF. Placebo effects in oncology. J Natl Cancer Inst 2003; 95: 19-29.
26. Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994; 121: 393-99.
27. Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990; 82: 1127-32.
28. Willox JC, Corr J, Shaw J, Richardson M, Calman KC, Drennan M. Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed) 1984; 288: 27.
29. Slaviero KA, Read JA, Clarke SJ, Rivory LP. Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy. Nutr Cancer 2003; 46: 148-57.
30. Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Nutritional deterioration in cancer: the role of disease and diet. Clin Oncol (R Coll Radiol) 2003; 15: 443-50.
31. Walsh D, Mahmoud F, Barna B. Assessment of nutritional status and prognosis in advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory nutritional index. Support Care Cancer 2003; 11: 60-62.
32. Koch J. The role of body composition measurements in wasting syndromes. Semin Oncol 1998; 25: 12-19.
33. Blagden SP, Charman SC, Sharples LD, Magee LR, Gilligan D. Performance status score: do patients and their oncologists agree? Br J Cancer 2003; 89: 1022-27.
34. Schaafsma J, Osoba D. The Karnofsky Performance Status Scale re-examined: a cross-validation with the EORTC-C30. Qual Life Res 1994; 3: 413-24.
35. Jatoi A, Hillman S, Stella PJ, et al. Daily activities: exploring their spectrum and prognostic impact in older, chemotherapy-treated lung cancer patients. Support Care Cancer 2003; 11: 460-64.
36. Firat S, Byhardt RW, Gore E. Comorbidity and Karnofksy performance score are independent prognostic factors i n stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002; 54: 357-64.
37. Osoba D. What has been learned from measuring health-related quality of life in clinical oncology. Eur J Cancer 1999; 35: 1565-70.
38. Wilson KA, Dowling AJ, Abdolell M, Tannock IF. Perception of quality of life by patients, partners and treating physicians. Qual Life Res 2000; 9: 1041-52.
39. Cohen SR, Leis A. What determines the quality of life of terminally ill cancer patients from their own perspective? J Palliat Care 2002; 18: 48-58.
40. Greisinger AJ, Lorimor RJ, Aday LA, Winn RJ, Baile WF. Terminally ill cancer patients. Their most important concerns. Cancer Pract 1997; 5: 147-54.
41. Steinhauser KE, Christakis NA, Clipp EC, McNeilly M, McIntyre L, Tulsky JA. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 2000; 284: 2476-82.
42. Cella D, Chang CH, Lai JS, Webster K. Advances in quality of life measurements in oncology patients. Semin Oncol 2002; 29: 60-68.
43. Waldron D, O'Boyle CA, Kearney M, Moriarty M, Carney D. Quality-of-life measurement in advanced cancer: assessing the individual. J Clin Oncol 1999; 17: 3603-11.
44. Nordin K, Steel J, Hoffman K, Glimelius B. Alternative methods of interpreting quality of life data in advanced gastrointestinal cancer patients. Br J Cancer 2001; 85: 1265-72.
45. Ballatori E. Unsolved problems in evaluating the quality of life of cancer patients. Ann Oncol 2001; 12: S11-13.
46. Holzner B, Kemmler G, Sperner-Unterweger B, et al. Quality of life measurement in oncology - a matter of the assessment instrument? Eur J Cancer 2001; 37: 2349-56.
47. Hakamies-Blomqvist L, Luoma ML, Sjostrom J, et al. Timing of quality of life (QoL) assessments as a source of error in oncological trials. J Adv Nurs 2001; 35: 709-16.
48. Conroy T, Bleiberg H, Glimelius B. Quality of life in patients with advanced colorectal cancer: what has been learnt? Eur J Cancer 2003; 39: 287-94.
49. Wasson J, Keller A, Rubenstein L, Hays R, Nelson E, Johnson D. Benefits and obstacles of health status assessment in ambulatory settings. The clinician's point of view. The Dartmouth Primary Care COOP Project. Med Care 1992; 30: MS42-49.
50. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 1996; 125: 873-82.
51. Sarna L. Fluctuations in physical function: adults with non-small cell lung cancer. J Adv Nurs 1993; 18: 714-24.
52. Yadav RR, Fossella F, Palmer JL, et al. An objective evaluation of functional ability (OEF) in patients with advanced lung cancer. Proc Am Soc Clin Oncol 2003; 22: 746.
53. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998; 25: 43-46.
54. Moses AW, Slater C, Preston T, Barber MD, Fearon KC. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 2004; 90: 996-1002.
55. Ma J, Barbenel JC. A new ambulatory monitoring instrument of posture and mobility related activities. Biomed Sci Instrum 1997; 33: 88-93.
56. Matsuoka S, Yonezawa Y, Maki H, et al. A microcomputer-based daily living activity recording system. Biomed Sci Instrum 2003; 39: 220-23.
57. Aminian K, Robert P, Buchser EE, Rutschmann B, Hayoz D, Depairon M. Physical activity monitoring based on accelerometry: validation and comparison with video observation. Med Biol Eng Comput 1999; 37: 304-308.
58. Makikawa M, Kurata S, Kawato M, Kobayashi H, Takahashi A, Tokue R. Ambulatory physical activity monitoring system. Medinfo 1998; 9: 277-81.